NGC Update Service: December 23, 2013
Agency for Healthcare Research and Quality (AHRQ) sent this bulletin at 12/24/2013 09:00 AM ESTDecember 23, 2013
New This Week
Guideline SummariesAmerican Association of Clinical Endocrinologists
American Association of Neuroscience Nurses Program in Evidence-based Care
University of Texas at Austin School of Nursing, Family Nurse Practitioner Program
Withdrawn SummariesThese summaries have been withdrawn from the NGC Web site because they no longer meet the NGC Inclusion Criteria with respect to date, or because the guideline developer has indicated that they are no longer current. See the Guideline Archive for a complete list of all guidelines that have been withdrawn from the NGC Web site. Please refer to NGC's FAQ page if you have additional questions about guidelines recently withdrawn. Infectious Diseases Society of America
Kaiser Permanente Care Management Institute
National Collaborating Centre for Cancer
National Collaborating Centre for Primary Care
|
Announcements
How to Participate
- Submit guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.
- Suggest a guideline for possible inclusion: Submit your suggestions for evidence-based guidelines that you would like to see included in NGC.
- Suggest a Guideline Synthesis topic: We welcome your suggestions for guideline synthesis topics!
Revised Inclusion Criteria
NGC has revised its Inclusion Criteria! Visit our updated Inclusion Criteria page to see the new criteria and send us your comments.
Conference News
- The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.
U.S. Food and Drug Administration (FDA) Advisory
- December 17, 2013: Methylphenidate ADHD Medications: FDA is warning that methylphenidate products, one type of stimulant drug used to treat attention deficit hyperactivity disorder (ADHD), may in rare instances cause prolonged and sometimes painful erections known as priapism. Based on a recent review of methylphenidate products, FDA updated drug labels and patient Medication Guides to include information about the rare but serious risk of priapism. If not treated right away, priapism can lead to permanent damage to the penis.
NGC's Sister Resources
- Find Innovations and QualityTools classified by disease or clinical category, patient population, setting of care, stage of care, and more in AHRQ's Health Care Innovations Exchange Web site.
- Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).